Cover Image
市場調查報告書

Opioids(類鴉片物質)市場未來展望:西歐的Opioids(類鴉片物質)市場

Opioids Market Overview to 2023 - Opioids in Western Europe

出版商 CBR Pharma Insights 商品編碼 318490
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
Opioids(類鴉片物質)市場未來展望:西歐的Opioids(類鴉片物質)市場 Opioids Market Overview to 2023 - Opioids in Western Europe
出版日期: 2014年10月31日 內容資訊: 英文 74 Pages
簡介

在醫療現場使用Opioids(類鴉片物質)一直是長年來爭議的焦點。雖然眾所周知Opioids(類鴉片物質)是疼痛的止痛劑,但由於其誤用可能性高,每個國家的法規當局都在苦於如何在使用的優點及誤用的危險性中取得平衡點。但近年來由於藥物濫用抑製劑的開發,而出現了一面抑制誤用的可能性一面給予Opioids(類鴉片物質)來疼痛管理這樣的趨勢。近年來的藥物開發也正在研發可抑制(妨礙普及化)的藥物誤用可能性產品。此外,也有替代性產品(美沙酮,Buprenornhine等)的開發、使用。就國別來看,英國佔市佔率52%,德國次之(20%),同時西班牙市場佔有率最低(以數量為準3.3%,以金額為準2.2%)。

本報告提供西歐各國(英國·德國·法國·義大利·西班牙)的Opioids(類鴉片物質)方面,疼痛管理用Opioids(類鴉片物質)的使用方法和替代性的治療方式,Opioids(類鴉片物質)的使用宣言,濫用抑製藥概要和對市場的影響度,域內整體市場趨勢預測(今後10年份),各國市場詳細結構與趨勢(消費量·收益額,使用法規,市場促進·阻礙因素等),主要的開發中產品概要等資訊,為您概述為以下內容。

摘要整理

Opioids(類鴉片物質)的概要

  • 疼痛管理上的Opioids(類鴉片物質)
  • 使用限制
  • 國際會議

西歐各國的藥物誤用

  • 藥物誤用展開
  • 濫用抑製藥的影響
  • 主要的濫用抑制產品

疼痛管理的未滿足需求

  • 必要條件與消費趨勢
  • 利用促進的主要活動

法規形勢

  • 可得性和使用法規之間的平衡

歐洲的Opioids(類鴉片物質)市場

  • 歐洲域內的消費趨勢
  • 市場收益額的估計值·預測值

各國市場現況(英國·德國·法國·義大利·西班牙)

  • 法規形勢
  • 消費趨勢
  • 需求數量·銷售量(以數量為準)
  • 針對法規和使用正當化的活動

市場發展

  • 主要的全球性品牌
  • 新的濫用抑制技術
  • 開發中產品
  • 市場新的趨勢
  • 企業整合策略

附錄

  • 簡稱/大寫字母集
  • 參考資料
目錄
Product Code: GBI053CBR

Summary

The report provides an estimation of 2013 opioid revenues and forecast consumption and revenues until 2023 in the five major Western European countries: the UK, Germany, France, Italy and Spain. The estimated revenues for 2013 are highest in the UK, which held a share of 52%, followed by Germany with 20%. Spain had the lowest in terms of both consumption (3.3%) and revenues (2.2%).

Their use for medicinal purposes has been highly controversial for several decades. Although recognized as potent painkillers, potential for misuse is high. As a result, all regulatory authorities strive to maintain a fine balance between enforcing strict regulations that will crack down on illicit usage but at the same time ensure accessibility for genuine medical purposes. Amidst concerns regarding inadequate pain management due to low accessibility, there are also concerns regarding a lack of significant clinical evidence of their role in managing chronic pain. However, new abuse-deterrent technologies provide an incentive to prescribe more opioids in pain management by alleviating concerns over misuse potential. The approval of such new drugs and formulations has proved a new impetus to growth in opioid usage in the five major Western European countries.

Opioids are largely used for two medicinal purposes: pain management and substitution treatment for drug dependence. Several of the recently approved and pipeline opioid analgesics have a strong focus on reducing misuse potential, which is one of the most significant barriers to usage in pain management. However, usage is on the rise following the introduction of new abuse-deterrent formulations of fentanyl and oxycodone, and initiatives that aim to rationalize usage in pain management. Demand is also high in substitution treatment. While both methadone and buprenorphine are approved for substitute treatment, buprenorphine usage increased in Europe after the approval of Suboxone in 2006, in combination with naloxone, a pure opioid antagonist that acts as an abuse-deterrent.

Scope

The report covers the five major Western European countries (the UK, Germany, France, Italy and Spain) and includes -

  • An overview of opioids in pain management and substitution treatment, and usage constraints for both
  • Brief analysis of recent approvals of key abuse-deterrent drugs and their impact on consumption and market growth
  • Country snapshots, comprising key regulations, consumption, market revenues, market forecasts and key drivers and barriers
  • An overview of new abuse-deterrent technologies and profiles of key pipeline products

Key Reasons to Purchase

  • Gain a perspective of the opioids market size and key drivers and challenges that dictate the market trends in each of the five major countries in Western Europe
  • Gauge the impact of key recently approved abuse-deterrent technologies on opioid usage
  • Develop an understanding of how the regulatory landscape affects market potential and growth in each country
  • Identify the key molecules that are currently the leading players in each region and those that hold the highest potential in the forecast period
  • Scan the pipeline for innovative products with abuse-deterrent technologies that could have an impact on opioid usage in the pain management market

Table of Contents

  • Executive summary
  • Opioids: an overview
    • Opioids in pain management
    • Usage constraints
    • International conventions
  • Drug misuse in Western Europe
    • Extent of drug misuse
    • Impact of abuse-deterrent drugs
    • Key abuse-deterrent products
  • Unmet need in pain management
    • Requirement and consumption
    • Key activities to promote usage
  • Regulatory landscape
    • Finding a balance between accessibility and regulations
  • Opioids market in Europe
    • Consumption trends in Europe
    • Estimated revenue and forecast
  • Country snapshots (UK, Germany, France, Italy, Spain)
    • Regulatory landscape
    • Consumption trends
    • Volume and revenue by molecule
    • Barriers and activities to rationalize usage
  • Market developments
    • Leading global brands
    • New abuse-deterrent technologies
    • Pipeline products
    • New developments
    • Strategic consolidations
  • Appendix
    • Abbreviations/acronyms
    • References
Back to Top